SEC Form 4/A · accession 0001140361-16-090143
AVADEL PHARMACEUTICALS PLC · AVDL
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
This is an amendment (Form 4/A). It replaces an earlier filing for the same period.
Reporting owner
Gregory J. Davis
Officer — See Remarks
Period of report
Dec 14, 2016
Accepted (ET)
Dec 16, 2016 · 9:36 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001012477
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| ADSsF1,F2 | Dec 14, 2016 | A | 10,000 | — | A | 30,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F5 | $10.40 | Dec 14, 2016 | A | 65,000 | A | — | Dec 14, 2026 | ADSs | 65,000 | 65,000 | D |
| Stock Option (right to buy)F3 | $21.67 | holding | — | — | — | — | Jun 26, 2025 | ADSs | 50,000 | 50,000 | D |
| Stock Option (right to buy)F4 | $14.35 | holding | — | — | — | — | Dec 10, 2025 | ADSs | 50,000 | 50,000 | D |
Explanation of responses
- F1The issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value 0.122 Euros per share, of the issuer; ADSs are represented by American Depositary Receipts. The securities acquired as reported in this statement represent the grant of ADSs under the issuer's "Free Share" award program; no purchase price was applicable to such grant. See footnote (2) for details as to the dates such ADSs will be issued to the reporting person.
- F2Includes (a) 20,000 restricted ADSs granted under the issuer's "Free Share" award program on 8/10/2016, all of which will be issued to the reporting person on the second anniversary of the grant date; and (b) 10,000 restricted ADSs granted under the issuer's "Free Share" award program on 12/14/2016, all of which will be issued to the reporting person on the second anniversary of the grant date.
- F3Options become exercisable as to 12,500 ADSs on each of the first four anniversaries after the 06/26/2015 grant date.
- F4Options become exercisable as to 12,500 ADSs on each of the first four anniversaries after the 12/10/2015 grant date.
- F5Options become exercisable as to 16,250 ADSs on each of the first four anniversaries after the 12/14/2016 grant date.
Remarks
VP, Corporate and Business Development Explanatory Note: This amendment is being filed to correct technical errors in the original filing caused by third party software. These errors resulted in the transactions and holdings appearing as a duplication of the transactions and holdings reported on a separate Form 4 filed on the date hereof by the individual who signed the original report as attorney-in-fact.